Boule Diagnostics Future Growth
Future criteria checks 4/6
Boule Diagnostics is forecast to grow earnings and revenue by 108.3% and 6.4% per annum respectively. EPS is expected to grow by 108.2% per annum. Return on equity is forecast to be 12.2% in 3 years.
Key information
108.3%
Earnings growth rate
108.2%
EPS growth rate
Medical Equipment earnings growth | 14.2% |
Revenue growth rate | 6.4% |
Future return on equity | 12.2% |
Analyst coverage | Low |
Last updated | 22 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 647 | 51 | 24 | 62 | 2 |
12/31/2025 | 594 | 44 | 22 | 59 | 2 |
12/31/2024 | 562 | -94 | 15 | 55 | 2 |
9/30/2024 | 563 | -213 | -24 | 61 | N/A |
6/30/2024 | 573 | 21 | -7 | 83 | N/A |
3/31/2024 | 576 | 27 | -15 | 73 | N/A |
12/31/2023 | 571 | 25 | -31 | 51 | N/A |
9/30/2023 | 572 | 19 | -43 | 36 | N/A |
6/30/2023 | 558 | 17 | -81 | -8 | N/A |
3/31/2023 | 559 | 16 | -91 | -19 | N/A |
12/31/2022 | 548 | 13 | -86 | -11 | N/A |
9/30/2022 | 539 | 27 | -87 | -13 | N/A |
6/30/2022 | 525 | 32 | -56 | 14 | N/A |
3/31/2022 | 495 | 28 | -32 | 29 | N/A |
12/31/2021 | 463 | 23 | -13 | 43 | N/A |
9/30/2021 | 416 | -27 | 3 | 57 | N/A |
6/30/2021 | 403 | -13 | 14 | 64 | N/A |
3/31/2021 | 383 | -55 | 25 | 73 | N/A |
12/31/2020 | 400 | -48 | 29 | 75 | N/A |
9/30/2020 | 437 | -8 | 26 | 70 | N/A |
6/30/2020 | 470 | -8 | 29 | 76 | N/A |
3/31/2020 | 499 | 35 | 26 | 73 | N/A |
12/31/2019 | 499 | 38 | 6 | 54 | N/A |
9/30/2019 | 476 | 32 | -14 | 41 | N/A |
6/30/2019 | 456 | 21 | -37 | 16 | N/A |
3/31/2019 | 444 | 36 | -59 | 11 | N/A |
12/31/2018 | 424 | 41 | -42 | 23 | N/A |
9/30/2018 | 425 | 48 | -13 | 40 | N/A |
6/30/2018 | 424 | 60 | N/A | 51 | N/A |
3/31/2018 | 421 | 43 | N/A | 46 | N/A |
12/31/2017 | 428 | 37 | N/A | 58 | N/A |
9/30/2017 | 422 | 31 | N/A | 45 | N/A |
6/30/2017 | 421 | 28 | N/A | 38 | N/A |
3/31/2017 | 419 | 38 | N/A | 32 | N/A |
12/31/2016 | 397 | 36 | N/A | 20 | N/A |
9/30/2016 | 383 | 36 | N/A | 20 | N/A |
6/30/2016 | 364 | 22 | N/A | 28 | N/A |
3/31/2016 | 341 | 15 | N/A | 29 | N/A |
12/31/2015 | 331 | 15 | N/A | 22 | N/A |
9/30/2015 | 333 | 29 | N/A | 22 | N/A |
6/30/2015 | 318 | 33 | N/A | 8 | N/A |
3/31/2015 | 309 | 33 | N/A | 21 | N/A |
12/31/2014 | 307 | 30 | N/A | 31 | N/A |
9/30/2014 | 289 | 14 | N/A | 16 | N/A |
6/30/2014 | 285 | -68 | N/A | 35 | N/A |
3/31/2014 | 287 | -64 | N/A | 23 | N/A |
12/31/2013 | 277 | -70 | N/A | 16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8BD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 8BD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 8BD is expected to become profitable in the next 3 years.
Revenue vs Market: 8BD's revenue (6.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 8BD's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8BD's Return on Equity is forecast to be low in 3 years time (12.2%).